GE HealthCare Technologies financials
$66.46−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $20.63B | $19.67B | $19.55B |
| Gross profit | $8.25B | $8.21B | $7.92B |
| Gross margin | 40.0% | 41.7% | 40.5% |
| Operating income | $3.05B | $3.03B | $2.82B |
| Net income | $2.08B | $1.99B | $1.39B |
| Net margin | 10.1% | 10.1% | 7.1% |
| Diluted EPS | $4.55 | $4.34 | $3.03 |
| EBITDA | $3.63B | $3.61B | $3.43B |
| Operating cash flow | $1.99B | $1.95B | $2.10B |
| Free cash flow | $1.50B | $1.55B | $1.71B |
| Diluted shares | 458.0M | 459.0M | 458.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $4.51B | $2.89B | $2.50B |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $10.00B | $8.95B | $9.44B |
| Total assets | $36.91B | $33.09B | $32.45B |
| Total liabilities | $26.31B | $24.44B | $25.14B |
| Shareholders' equity | $10.39B | $8.46B | $7.14B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology